Herpes Zoster - A Drug Pipeline Analysis Report by Technavio
LONDON--(BUSINESS WIRE)--Sep 18, 2018--Technavio has announced their latest . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of herpes zoster. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005980/en/
Technavio has published a new report on the drug development pipeline for the treatment of herpes zoster, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
Herpes zoster: An overview
Herpes zoster, which is also called as shingles, is a viral infection caused by the varicella-zoster virus. Varicella-zoster virus is also responsible for causing chickenpox infection. After chickenpox is cured, the virus remains in the nervous system and gets activated to cause herpes zoster. Herpes zoster can be characterized through the development of red skin rashes around the rib cage or waist, which causes pain and burning sensation. The infection appears in the form of blisters present in a strip fashion on one side of the body. These blisters usually occur on the torso, neck, or face. Old adults who have a weaker immune system are more prone to herpes zoster.
The individuals who are naturally infected with the wild-type of varicella-zoster virus or have had varicella vaccination can develop herpes zoster. Older adults have a considerable risk of getting herpes zoster when compared to children. According to CDC, in the US, 99.5% of the people above the age of 40 years are prone to be infected by the varicella-zoster virus. Usually, one out of three people in the US will develop herpes zoster in their lifetime.
Herpes zoster: Segmentation of pipeline molecules
Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with around 23% of the pipeline molecules administered through this mode.
Between companies and institutions, institution led the drug development space for the treatment of herpes zoster. Various institutes, universities, and hospitals are conducting research and studies for the treatment of herpes zoster. The major institutes that are involved in the pipeline drug development are the University of Sydney, National Institute of Aging (NIA), and the National Centre for Complementary and Integrative Health (NCCIH). Some of the key players include Bausch & Lomb, EMS Pharma, GlaxoSmithKline, and GREEN CROSS.
Some of the key topics covered in the report include:
1. Scope of the Report
2. Regulatory Framework
3. Drug Development LandscapeDrugs under development
4. Drug Development StrategiesTherapies employed Route of administration Therapeutic modality Mechanism of action
5. Recruitment StrategiesGeographical coverage Recruitment status Gender Age
6. Key CompaniesType of players Company overview
7. Discontinued and Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005980/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/18/2018 02:04 PM/DISC: 09/18/2018 02:04 PM